Outlook Therapeutics’ stock plummeted 80% as its wet AMD drug failed key trial, though it saw vision improvements.

Outlook Therapeutics’ stock dropped by 80% after its ONS-5010 drug failed to meet the primary endpoint in a clinical trial against Roche's Lucentis for treating wet AMD. Despite the setback, the company noted improvements in vision and safety, with full results expected in January 2025. The company plans to resubmit its application for U.S. approval in the first quarter of 2025, though it already has approval in Europe.

November 27, 2024
6 Articles